Revolutionary Gene Therapy Restores Hearing in Patients Born Deaf Within Weeks

A groundbreaking gene therapy trial has successfully restored hearing in all ten patients born with congenital deafness or severe hearing loss, with some participants experiencing dramatic improvements within just weeks of treatment. The study, published in Nature Medicine, represents a major breakthrough in genetic treatments for hearing loss and offers hope to millions of people worldwide affected by inherited forms of deafness.

The trial, conducted by researchers at Karolinska Institutet in collaboration with hospitals and universities in China, focused on patients aged 1 to 24 who suffered from a genetic form of deafness caused by mutations in the OTOF gene. These mutations prevent the body from producing sufficient amounts of otoferlin, a protein essential for transmitting sound signals from the inner ear to the brain. The therapy used a synthetic adeno-associated virus to deliver a working version of the OTOF gene directly into the inner ear through a single injection.

"This is a huge step forward in the genetic treatment of deafness, one that can be life-changing for children and adults," said Maoli Duan, consultant and docent at the Department of Clinical Science, Intervention and Technology at Karolinska Institutet and one of the study's corresponding authors. The results appeared remarkably quickly, with most patients beginning to regain some hearing within one month of treatment.

After six months, all participants showed clear improvement in their hearing ability. On average, the level of sound they could detect improved dramatically from 106 decibels to 52 decibels. Children showed the most impressive responses, particularly those between ages five and eight. One seven-year-old girl regained nearly full hearing and was able to have everyday conversations with her mother just four months after receiving the injection.

The therapy proved safe and well-tolerated throughout the study period, with the most commonly reported side effect being a temporary decrease in neutrophils, a type of white blood cell. No serious adverse reactions were observed during the follow-up period. The success of this trial paves the way for expanding gene therapy approaches to other, more common genetic causes of deafness, including mutations in genes such as GJB2 and TMC1, offering hope for treating a broader range of inherited hearing disorders.